Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-valent HPV vaccination at months 0, 1 and 6
- Development stage
- Unknown
- Lead developer
- Xiamen Innovax Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
9-valent HPV vaccination at months 0, 1 and 6 refers to a three-dose immunization regimen of a recombinant 9-valent human papillomavirus (9vHPV) vaccine (such as Cecolin 9, developed by Xiamen Innovax and Wantai BioPharm) administered at months 0, 1, and 6. This specific regimen is being evaluated in clinical trials sponsored by the Jiangsu Province Centers for Disease Control and Prevention to assess the safety, immunogenicity, and memory B-cell response of sequential 9vHPV vaccination in healthy females aged 18–45 who have previously completed a bivalent HPV vaccine series. The vaccine consists of recombinant L1 capsid protein virus-like particles (VLPs) targeting nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58) adsorbed onto an aluminum hydroxide adjuvant, designed to elicit protective neutralizing antibodies and prevent cervical cancer, genital warts, and other HPV-associated diseases.
- Brand names
- Cecolin 9Cecolin9Cecolin-9
- Other names
- 9-valent HPV vaccination at months 0 , 1 and 69-valent HPV vaccination at months 0, 1 and 69-valent HPV vaccine9vHPV vaccinerecombinant human papillomavirus 9-valent vaccine
02
Targets
HPV11 L1HPV16 (Human papillomavirus type 16)Human papillomavirus type 18 L1 major capsid proteinHPV31 L1HPV33 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)HPV18 L1
Beyond the preview
Go deeper on 9-valent HPV vaccination at months 0, 1 and 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-valent HPV vaccination at months 0, 1 and 6.